Pharmacyclics chief wins $3.6bn from takeover That is a seventy-fold plus return for Robert Duggan, who amassed his stake in 2009 when the share price was languishing at $1. AbbVie dug deep to outbid four rival suitors for the Californian group, stoking fears that big pharma is overpaying for biotech groups. (FT)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.